This program offers 1 participatory MCLE credit. You must register in advance to participate.
Presented by the International Interest Group and the Patent Interest Group.
R&D on antibody drugs has drawn increasing attention since 2017, when Nobel laureate Tasuku Honjyo developed the world renowned anti-cancer drug Optivo.
In light of Japanese patent practice, pharmaceutical companies and research institutes face new challenges on the scope of patent protection when filing applications related to antibody drug patents. In his presentation, Dr. Iida will provide a brief outline of the patent practice related to antibody drugs and how you can prepare your specification to cover a broad scope of protection in Japan.
Dr. Masato Iida has extensive experience and expertise in biochemistry, molecular biology, and pharmaceuticals. He has been devoted to enhancing the IP portfolio of pharmaceutical companies, universities, and research institutes for over a decade. Prior to joining Shiga, he worked as a researcher in the field of molecular biology in a mega pharmaceutical company.
Moderator: Mariana Noli